TEVA · Teva reported Q3 2026 non-GAAP diluted EPS of $0.86, beating the $0.72…

Teva reported Q3 2026 non-GAAP diluted EPS of $0.86, beating the $0.72 consensus by 19.4%, while revenue of $4.395B came in above the $4.23B estimate. The beat was driven by strong innovative brand growth (AUSTEDO +21%, AJOVY +61%, UZEDY +96% YoY) and record non-GAAP gross margin of 58.7%, though total revenue declined 2% YoY due to generic erosion from lenalidomide competition. Teva raised its 2026 revenue outlook for all three key brands and increased its non-GAAP operating income guidance, offset by higher acquired IPR&D charges.

• Non-GAAP diluted EPS of $0.86 vs consensus $0.72, a beat of 19.4%
• Revenue of $4.395B vs consensus $4.23B, above estimates
• Total revenue declined 2% YoY to $4.395B, driven by 39% drop in U.S. generic product revenues due to lenalidomide competition
• Non-GAAP gross margin reached 58.7%, the highest quarterly level in the last decade (excluding Q4 2025 milestone payments)